Executive summary
Three-sentence thesis. TD SYNNEX is the #1/#2 global IT-product distributor, a high-volume / razor-thin-margin business (about 2% operating margin on net revenue) whose true economics live in working-capital float and free cash flow rather than reported earnings. The stock has risen roughly 118% in the last twelve months because a memory/component-price super-cycle has temporarily inflated average selling prices and earnings, while its Hyve (HIVE) contract-assembly unit rides the AI data-center boom (+95% YoY in Q1 FY2026) -- but the underlying business still earns a return on invested capital (about 10%) that barely clears its cost of capital (about 10%). At $269 the market is paying roughly 26x normalized earnings and a ~5.7% free-cash-flow yield for a business with no durable moat, a +0.1-point ROIC-WACC spread, and a customer/vendor concentration profile (one customer 11%, Apple 12%, HP 10% of revenue) that caps long-term quality.
Verdict: REJECT at current price. WAIT for a much lower entry. Quality grade C+. This is a competent, well-run, cash-generative distributor -- not a compounder -- and it is priced as if the cyclical peak is permanent. I would want the stock in the $120-150 range (roughly 12-15x through-cycle earnings, ~8-10% FCF yield) before the risk/reward justifies a position.
Key metrics dashboard
| Metric | Value | Read |
|---|---|---|
| Price / Market cap | $268.80 / $21.6B | Near 52-week high ($279) |
| FY2025 revenue (net) | $62.5B | +6.9% YoY |
| FY2025 GAAP EPS (diluted) | $9.95 | 10-K, FY2025 |
| TTM GAAP EPS (diluted) | ~$12.0 | Inflated by Q1 FY2026 spike |
| Operating margin (net rev) | ~2.3% FY25, 2.85% Q1 FY26 | Structurally thin |
| ROE (FY2025) | 9.8% | Below 15% Buffett test |
| ROIC (through-cycle) | ~10.3% | Barely above WACC |
| WACC (est.) | ~10.2% | ROIC-WACC ~+0.1 pt |
| FY2025 FCF | $1.39B | Genuine cash engine |
| FCF yield (FY25) | ~6.4% | Cyclical peak |
| Net leverage | 1.1x | Conservative |
| Cash conversion cycle | ~23 days | Excellent, improving |
| Dividend yield | ~0.7% | Token; buyback-led return |
| Normalized P/E | ~26x | Peak-cycle pricing |
1. Business model: what SNX actually is
1.1 TD SYNNEX was formed by the September 2021 merger of SYNNEX and Tech Data, creating the world's largest (or co-largest, with Ingram Micro) "broadline" IT distributor and solutions aggregator. It sits between roughly 1,500 technology vendors (OEMs) and roughly 150,000 reseller/VAR/retail customers, buying hardware, software, and cloud services in bulk and reselling them, providing logistics, credit, configuration, technical enablement, and a digital ordering platform.
1.2 Two businesses (segments re-cast in Q1 FY2026):
- Distribution (~85% of billings): three regional segments (Americas, Europe, APJ). Endpoint Solutions (PCs, peripherals) and Advanced Solutions (cloud, security, software, servers, networking). Operating margin ~2.0% of gross billings.
- Hyve (HIVE) (
15% of billings, ~27% of operating income in Q1 FY2026): an ODM / hyperscale design-and-assembly business that builds complete server and networking racks for a small number of cloud hyperscaler customers. Grew +95% YoY in Q1 FY2026 on AI data-center demand. Higher margin (4.2% of billings) but lumpier and concentrated.
1.3 The economics are float economics. A distributor earns ~2% on revenue but turns inventory ~6x/yr and runs a low cash conversion cycle (CCC ~23 days FY2025; DSO 74, DIO 60, DPO 111). Suppliers and the AR-securitization facility effectively finance the inventory. This is why FCF ($1.39B FY2025) exceeds the quality signal you would infer from a 1.3% net margin: the balance sheet is a working-capital machine, not an asset-heavy one.
1.4 Reported "debt/equity" of ~3.0x is misleading: most of the $26B of liabilities is trade payables (the float), not financial leverage. Actual financial debt is $4.6B against $2.4B cash = $2.2B net debt, net leverage 1.1x, gross 2.4x. The balance sheet is sound.
2. Phase 1 - Risk analysis (inversion: how do I lose money here?)
I invert: what set of facts would make $269 a permanent capital loss?
Risk register
| # | Risk | Severity (drawdown) | Likelihood (5yr) | Expected loss |
|---|---|---|---|---|
| R1 | Memory/ASP super-cycle reverses; EPS normalizes and the ~26x peak multiple compresses to a deserved ~12x | -45% | 55% | -24.8% |
| R2 | AI data-center / HIVE demand cools or a hyperscaler in-sources; +95% growth engine stalls | -20% | 40% | -8.0% |
| R3 | PC/server demand destruction from higher component-cost pass-through (volume elasticity bites) | -15% | 35% | -5.3% |
| R4 | Loss/deterioration of a top vendor (Apple 12%, HP 10%) or the 11% customer | -25% | 15% | -3.8% |
| R5 | Margin compression from distributor price competition / vendor direct-to-reseller shift | -15% | 30% | -4.5% |
| R6 | Macro recession compresses IT spending; working capital unwind hits a levered balance sheet | -20% | 25% | -5.0% |
| Total expected (non-additive) | ~-30% to -40% |
2.1 R1 is the dominant risk and the core of the thesis. Management was explicit on the Q4 FY2025 and Q1 FY2026 calls: memory (DRAM/NAND) prices "increased dramatically," driving ASP increases on PCs, servers, and storage; approximately 2 percentage points of Q1 FY2026 gross-billings growth came from higher ASPs plus modest pull-forward, plus a 10-15 bps gross-margin benefit from "strategic inventory purchasing." Distributors are pass-through agents -- when component prices spike, billings and dollar margins inflate without any improvement in the underlying franchise. When prices normalize (and memory is famously cyclical), the EPS tailwind reverses. Paying 26x for an EPS number that includes a transient inflation kicker is the trap.
2.2 R2 - HIVE concentration. HIVE's +95% growth depends on two hyperscaler customers. Contract assembly for hyperscalers is a low-moat business: hyperscalers are sophisticated, price-sensitive, and routinely dual-source or in-source. Management itself flagged that new-customer/program ramps "take time" (impact "towards end of FY2026 and 2027"), i.e., today's growth rests on a narrow base. If AI capex digestion arrives, HIVE -- the highest-margin, highest-growth piece -- is the most exposed.
2.3 R4 - structural concentration. The 10-K discloses one customer at 11% of revenue (FY2025) and vendors Apple (12%) and HP (10%). Vendor agreements are short-term, non-exclusive, terminable on short notice. This is the permanent ceiling on distributor quality: the franchise does not control its own supply or demand.
2.4 Tail risks (non-additive): a credit event in the AR-securitization market during a recession (working-capital unwind + funding stress simultaneously); a goodwill writedown ($4.1B goodwill + $3.8B intangibles vs $8.5B equity -- nearly all book value is merger goodwill, though no impairment to date); a disruptive shift to vendor direct-fulfillment / marketplace models that disintermediates broadline distribution over a decade.
3. Phase 2 - Financial analysis
3.1 Multi-year performance (fiscal years ending Nov 30)
| FY | Revenue ($B) | Op margin (net) | Net income ($M) | ROE | ROIC | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2021 | 31.6 (partial Tech Data yr) | 2.3% | 395 | 5.0% | 5.4% | 810 | 755 |
| 2022 | 62.3 | 2.0% | 651 | 8.1% | 8.2% | -50 | -167 |
| 2023 | 57.6 | 1.9% | 627 | 7.7% | 8.8% | 1,407 | 1,257 |
| 2024 | 58.5 | 2.1% | 689 | 8.6% | 8.8% | 1,218 | 1,043 |
| 2025 | 62.5 | 2.3% | 828 | 9.8% | 9.6% | 1,532 | 1,389 |
3.2 The numbers tell a consistent story: a 2%-margin, ~9% ROE/ROIC business that generates real cash. ROE has improved from 5% to ~10% post-merger as integration synergies landed, but it remains below the 15% Buffett threshold and below most quality compounders. Free cash flow is genuine and lumpy -- note FY2022's negative FCF (working-capital build) versus FY2025's $1.39B. Three consecutive years of >$1B FCF is a real achievement and the best thing about the business.
3.3 ROIC vs WACC (the decisive calculation)
- Through-cycle NOPAT ~ $1.10B; invested capital (equity + debt - cash) ~ $10.6B -> ROIC ~ 10.3%.
- WACC: cost of equity = 4.3% rf + 1.44 beta x 5% ERP = 11.5%; after-tax cost of debt ~ 4.2%; weights ~82% equity / 18% debt -> WACC ~ 10.2%.
- ROIC - WACC ~ +0.1 point. SNX creates essentially zero economic value above its cost of capital. Growth at a ~0-spread does not create value -- it merely recycles capital. This is the single most important fact in the analysis and the reason this cannot command a premium multiple.
3.4 Owner earnings and free cash flow
- 3-year average FCF ~ $1.23B; FY2025 FCF $1.39B (a strong-cash-flow year, partly aided by a few-hundred-million Q4 timing benefit that reverses in Q1 FY2026, per the CFO).
- FCF/share (3-yr avg) ~ $15.3; FY2025 ~ $17.3.
- FCF yield at $269: ~5.7% (3-yr avg) to ~6.4% (FY2025 peak). For a no-moat, ~10%-ROIC distributor, a high-single-digit FCF yield is the minimum I would require; a mid-single-digit yield at a cyclical peak is unattractive.
3.5 Normalization (why I do not use TTM EPS)
TTM GAAP EPS ($12.0) and the Q1 FY2026 quarter (+69% non-GAAP EPS, +104% GAAP EPS) are inflated by the ASP/memory super-cycle and a HIVE surge. Stripping the cyclical kicker -- normalized net revenue ~$68B at a through-cycle ~2.1% operating margin, less ~$350M interest, at a 23% tax rate -- yields normalized EPS ~ $10.2. At $269 that is **26x normalized earnings**, an extraordinary multiple for this business class.
3.6 Valuation
DCF (FCFF, through-cycle owner earnings), equity value per share:
| Discount rate | g = 3% | g = 5% | g = 7% |
|---|---|---|---|
| Base FCF $1.1B, 9% | $190 | $217 | $257 |
| Base FCF $1.1B, 10% | $161 | $184 | $217 |
| Base FCF $1.1B, 11% | $139 | $159 | $187 |
| Base FCF $1.3B, 10% | $195 | $222 | $261 |
Multiple cross-check on normalized EPS (~$10.2) and FY2025 GAAP diluted EPS ($9.95, per 10-K):
| Multiple | Value (on ~$10.2 EPS) |
|---|---|
| 10x | ~$102 |
| 11x | ~$113 |
| 12x | ~$123 |
| 13x | ~$134 |
3.7 Reconciling the two lenses. The DCF ($160-260, centered ~$200-220 at 10%) is more generous than the multiple lens ($100-135) because DCF credits SNX's outsized cash conversion (float pushes FCF well above accounting earnings). The honest answer sits between, weighted toward the multiple lens: a ~0-spread business deserves no premium, and the DCF's generosity rests on assuming the FCF base and a 3-7% perpetual growth rate hold -- neither is guaranteed for a cyclical pass-through agent. My fair-value range is $150-210, midpoint ~$180. At $269 the stock trades 28-49% above fair value.
4. Phase 3 - Moat analysis
4.1 Moat verdict: Narrow, and arguably None on a strict test. I score it Narrow only because of scale-driven cost advantage and modest switching friction; it is not a wide moat by any measure.
4.2 Moat sources, measured:
- Scale / cost advantage (the only real one): $62B+ of purchasing volume gives buying power, logistics density, and the ability to extend credit at scale. The broadline distribution industry is a 3-player oligopoly (TD SYNNEX, Ingram Micro, and regional players), and scale is a genuine barrier to a new entrant. But scale advantage between the two giants is symmetric -- it protects the industry, not SNX specifically, and it does not produce pricing power (margins are ~2% and flat).
- Switching costs (weak): resellers integrate with SNX's ordering platform, credit lines, and configuration services. Real but low -- multi-sourcing across distributors is standard.
- No brand, no network effect, no regulatory moat, no IP. The "making IT personal" branding and digital portal are table stakes, not a moat.
4.3 Durability test - what erodes the advantage? Vendor direct-fulfillment and cloud marketplaces (AWS Marketplace, Azure, hyperscaler self-service) are the structural threat: as software and cloud move to consumption/marketplace models, the broadline distributor's role as physical-product intermediary shrinks. The rising gross-to-net adjustment (29% -> 33%) is the visible fingerprint of this mix shift toward netted software/cloud -- revenue "disappears" into agency treatment. The moat is slowly narrowing, not widening.
4.4 Evidence the moat is weak: flat ~2% margins for years, ~10% ROIC, ~+0.1 ROIC-WACC spread, no pricing power (passes vendor price increases straight through), short-term terminable vendor contracts. A wide moat shows up as durable high returns on capital; SNX has durable mediocre returns.
5. Phase 4 - Decision synthesis
5.1 Management and capital allocation
5.2 CEO Patrick Zammit (ex-Tech Data, CEO since 2024); CFO David Jordan. Capital allocation is the strongest qualitative point: disciplined buybacks ($173M Q4, $2.2B over three years = ~61% of FCF), a token dividend ($0.48/qtr, ~0.7% yield), conservative net leverage (1.1x), staggered Senior Notes (2026/2028/2029/2031), proactive refinancing of the 2026 maturity, and a stated 50-75% FCF-return framework. Insider ownership is low (4.9%). MiTAC (the Taiwanese former-SYNNEX affiliate) historically held a large stake; ownership is now ~95% institutional. Management runs the business well -- the issue is the business, not the operators.
5.3 Expected-return tree (5-year, from $269)
- Bull (20%): memory/AI cycle stays elevated, HIVE diversifies to a 3rd/4th hyperscaler, multiple holds ~18x on growing EPS -> ~$340-380, ~5-7%/yr + buyback. Even the bull case is mediocre from this entry.
- Base (50%): ASP cycle normalizes, EPS reverts toward ~$10-11, multiple de-rates to ~13-15x -> ~$150-180, -7% to -12%/yr (capital loss).
- Bear (30%): memory cycle reverses hard + AI capex digestion + recession -> EPS ~$8-9, multiple ~10x -> ~$90-120, -15% to -20%/yr.
- Probability-weighted 5-yr return: roughly -5% to -8% annualized. Negative expected return at $269. The asymmetry is the wrong way around.
5.4 The Einhorn signal, in context
David Einhorn's Greenlight increased SNX in Q1 2026, which is what surfaced this name on the value screen. In context: Greenlight's SNX position is small (tens of thousands of shares; even a +749% increase is off a tiny base and remains a minor, non-top-holding position), and Einhorn has traded SNX before (owned 2020, exited, re-entered late 2024). This is consistent with a quantitative-cheapness / mean-reversion trade, not a concentrated conviction bet. I treat it as confirmation that the stock screened cheap on backward-looking multiples (low P/S, low EV/EBITDA) -- not as a reason to override the forward-looking ROIC and normalization work, which says the cheapness is a cyclical illusion.
5.5 Position sizing and entry prices
- Current action: do not buy. REJECT at $269.
- Accumulate below ~$150 (~14-15x through-cycle EPS, ~7.5% FCF yield) -- the point at which a no-moat distributor's cash generation starts to compensate for its lack of quality.
- Strong buy below ~$120 (~12x through-cycle EPS, ~9-10% FCF yield) -- a genuine margin of safety against the next memory-cycle downturn.
- Target allocation if it ever reaches the strong-buy zone: 1-2% (low, given no moat and high cyclicality).
5.6 Monitoring triggers
- Memory (DRAM/NAND) spot prices rolling over -> leading indicator of ASP-tailwind reversal.
- Gross-to-net adjustment trend (rising = software/cloud mix eroding the product-distribution role).
- HIVE customer count and operating margin (diversification beyond two hyperscalers = de-risking; concentration = caution).
- ROIC trend vs ~10% WACC (sustained break above 13% would change the quality verdict).
- Working-capital / cash conversion cycle in a downturn (the float must not become a liability).
6. Conclusion
6.1 TD SYNNEX is a well-managed, cash-generative, financially sound distributor that the market has mistaken for a growth compounder. The 118% one-year run is built on a memory-price super-cycle that inflated ASPs and EPS, plus an AI-data-center surge in a narrow, low-moat contract-assembly unit. Underneath, the franchise earns ~10% ROIC against a ~10% WACC -- it does not create durable economic value, and it has no wide moat, structural customer/vendor concentration, and a slowly narrowing role as software and cloud move to marketplace models.
6.2 At $269 (~26x normalized earnings, ~5.7% FCF yield) the price assumes the cyclical peak is permanent. My fair-value range is $150-210 (midpoint ~$180); the probability-weighted five-year return from here is negative. Verdict: REJECT at current price; revisit on a Buffett-style "fat pitch" only below ~$150, with a strong-buy line near ~$120. Patience, not participation, is the right move.
Citations
- TD SYNNEX 10-K FY2025 (filed 2026-01-27), SEC EDGAR: diluted EPS $9.95 (FY2025), $7.95 (FY2024), $6.70 (FY2023); customer concentration (one customer 11%/12%/11% of total revenue FY2025/2024/2023); vendor concentration (Apple 12%, HP 10% FY2025); $4.6B total borrowings; Senior Notes 2026/2028/2029/2031; $1.2B repurchase authorization remaining (Nov 30, 2025); no goodwill impairment; ~21.7% effective tax rate. (data/SEC-10K-FY2025.htm)
- TD SYNNEX 10-Q Q1 FY2026 (filed 2026-04-02), SEC EDGAR. (data/SEC-10Q-Q1FY2026.htm)
- Q4 FY2025 earnings call transcript (AlphaVantage): record EPS $3.83 (+24%), gross billings $24.3B, FY2025 FCF $1.4B, $742M returned, net leverage 1.1x, HIVE +50%, memory ASP commentary. (data/earnings-transcript-Q4-2025.md)
- Q1 FY2026 earnings call transcript (AlphaVantage): non-GAAP EPS $4.73 (+69%), gross billings $25.8B (+24%), HIVE +95% to $3.8B, ~2pts growth from ASP/pull-forward, segment recast. (data/earnings-transcript-Q1-2026.md)
- Financial statements (AlphaVantage INCOME_STATEMENT / BALANCE_SHEET / CASH_FLOW), processed via tools/process_financials.py. (data/financial-summary.md)
- Historical prices 2003-2026 (AlphaVantage TIME_SERIES_DAILY_ADJUSTED), processed via tools/process_prices.py. (data/price-summary.md)
- Company overview (AlphaVantage COMPANY_OVERVIEW). (data/company-overview.json)
- Greenlight Capital 13F context: Insider Monkey / ValueSider summaries of Q1 2026 holdings (used only as ownership-signal context, not as a valuation input).